Aptevo Therapeutics (NASDAQ:APVO) announced two additional frontline Acute Myeloid Leukemia (AML) patients have achieved ...

Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...

A study from Emory University suggests that levodopa, a medication that increases dopamine levels in the brain, may help ...

Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

In myeloma treatment, acute CRS is a common but treatable AE associated with CAR T-cell therapy and bispecific antibodies, ...

Groundbreaking HIV cure study in South Africa shows the safety and potential efficacy of a novel therapeutic regimen in women ...

Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, ...

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections ...